101
Participants
Start Date
February 4, 2019
Primary Completion Date
July 24, 2019
Study Completion Date
July 24, 2019
Long-Term Follow-Up of Patients who Received Engensis (VM202)
No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
Long-Term Follow-Up of Patients who Received Placebo
No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
EVMS (Eastern Virginia Medical School), Norfolk
Raleigh Neurology Associates, P.A., Raleigh
University of Florida McKnight Brain Institute, Gainesville
Clinical Research of West Florida, Tampa
Innovative Research of West Florida, Clearwater
Clinical Trials, Inc., Little Rock
Nerve and Muscle Center of Texas, Houston
Arizona Research Center, Phoenix
Neurological Research Institute, Santa Monica
Center for Clinical Research, San Francisco
Diablo Clinical Research, Inc., Walnut Creek
Northern California Research, Sacramento
Rainier Clinical Research Center, Inc., Renton
The Brigham and Women's Hospital, Boston
Helixmith Co., Ltd.
INDUSTRY